BioSig Technologies, Inc , together with its subsidiaries, operates as medical device company.
infoBioSig Technologies is a micro cap stock with a total market cap of 39.82M.
infoThey trade on the NASDAQ and had their IPO 8 years and 9 months ago.
infoBioSig Technologies currently employs 47 people.
infoAs of Wednesday, Aug 23 2023, BioSig Technologies’s share price is $0.5315.
News Relating to BioSig Technologies
InvestorPlace
Why Is BioSig Technologies (BSGM) Stock Up 19% Today?
Thursday Jul 20 2023 at 08:59
BioSig Technologies (NASDAQ: BSGM ) stock is rising higher on Thursday as subsidiary BioSig AI Sciences joins Nvidia’s (NASDAQ: NVDA ) Inception program. The Inception program is one that Nvidia uses to select companies with promising developments in the AI and data sciences spaces.
Zacks Investment Research
BioSig (BSGM) Inks New Deal to Advance AI in Electrophysiology
Thursday Jun 29 2023 at 12:54
The foundation of BioSig’s (BSGM) AI medical device platform is set to be built upon integrated healthcare datasets.
PennyStocks
The Benefits of Investing in Penny Stocks in the Long Term
Saturday Feb 11 2023 at 11:00
Why investing in penny stocks in the long term could be the right choice The post The Benefits of Investing in Penny Stocks in the Long Term appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
PennyStocks
4 Hot Penny Stocks To Buy For Under $1 Before Next Week
Thursday Oct 06 2022 at 15:05
Penny stocks under $1 to watch before next week. The post 4 Hot Penny Stocks To Buy For Under $1 Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Zacks Investment Research
3 Medical Instruments Stocks With Potential to Outperform
Thursday Sep 08 2022 at 14:18
Here we discuss ShockWave Medical (SWAV), CheckCap (CHEK) and Biosig Technologies (BSGM) that have the potential to outperform their industry going forward.
Benzinga
Bluejay Diagnostics (NASDAQ:BJDX), BioSig Technologies (NASDAQ:BSGM) – Sharps Technology And 2 Other Stocks Under $2 Insiders Are Aggressively Buying
Thursday Sep 08 2022 at 09:33
The Dow Jones closed higher by more than 400 points on Wednesday. Investors, meanwhile, focused on some notable insider trades.
Benzinga
(BSGM), (LDI) – BioSig Technologies, Reliance Global Group And 2 Other Penny Stocks Insiders Are Aggressively Buying
Thursday Sep 01 2022 at 09:21
U.S. stocks recorded losses for the fourth straight session on Wednesday. Investors, meanwhile, focused on some notable insider trades.
Proactive Investors
BioSig Technologies says Kansas City Heart Institute signs purchase agreement for its PURE EP System
Thursday Jul 07 2022 at 08:49
BioSig Technologies Inc has announced that Kansas City Heart Institute at Overland Park Regional Medical Center in Kansas City, USA, has signed a purchase agreement to acquire its PURE EP System. Following its evaluation of BioSig’s PURE EP System, Overland Park Regional Medical Center (OPRMC) has signed an agreement to purchase the technology under the terms of the company’s new program.
Proactive Investors
BioSig Technologies gets repeat ‘Outperform’ tag, $4 price target from Noble Capital
Thursday Jun 30 2022 at 11:23
BioSig Technologies Inc has earned a reiterated ‘Outperform’ rating and $4 price target from analysts at Noble Capital days after pricing a public offering that generated proceeds of $2.9 million. The offering was “[a] bit unexpected, timing-wise, but supports PURE EP commercialization,” the firm wrote.
Proactive Investors
BioSig Technologies says it intends to offer shares of its common stock in a “best efforts” underwritten public offering
Friday Jun 24 2022 at 06:45
BioSig Technologies, Inc. (NASDAQ:BSGM) has said it intends to offer shares of its common stock in a “best efforts” underwritten public offering. BioSig said it intends to use the net proceeds from the offering for the continuation of commercialization activities related to the PURE EP System, including additional support for organizational development, to fund working capital, and for general corporate purposes and other capital expenditures.
Proactive Investors
BioSig Technologies enters deal for Cleveland Clinic to evaluate its PURE EP signal processing platform
Wednesday Jun 22 2022 at 09:11
BioSig Technologies, Inc. (NASDAQ:BSGM) said it has entered into an evaluation agreement for its PURE EP System with Cleveland Clinic, its first following the induction of a new commercialization team to accelerate the process from product evaluation to adoption. The medical technology company said Cleveland Clinic, a non-profit multi-specialty academic medical center, will participate in a 60-day evaluation of BioSig’s signal processing platform.
Seeking Alpha
BioSig: PURE EP Economics Trade Exhausted
Tuesday Jun 14 2022 at 17:15
Despite numerous positive updates around its PURE EP segment, the market is agnostic in directional movements on the chart. Whilst the muddy waters on its PURE EP economics have been somewhat cleared, many uncertainties remain.
Proactive Investors
BioSig targets July 1 to launch national PURE EP commercial campaign
Thursday May 26 2022 at 10:17
BioSig Technologies Inc plans to kick off a national commercial launch campaign for its PURE EP System on July 1, 2022 following multiple initiatives to accelerate its transition from limited market release to nationwide availability. BioSig has more than 30 qualified leads ahead of the launch and to-date, more than 73 physicians have completed over 2,200 patient cases with the PURE EP System, the company said.
Proactive Investors
BioSig maintains ‘Outperform’ rating from Noble Capital as “stronger commercialization efforts” underway for its PURE EP system
Monday May 23 2022 at 10:12
BioSig Technologies Inc drew an ‘Outperform’ rating from Noble Capital, which noted that “stronger commercialization efforts” are underway for the company’s PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP systems after the first quarter. In a note to clients, Noble Capital analysts observed that BioSig recorded no PURE EP unit sales during the quarter, which was “below our expectations of three units”.
Proactive Investors
BioSig Technologies CEO Kenneth Londoner says the company has made great strides as it accelerates commercial momentum for its PURE EP system
Wednesday May 11 2022 at 10:20
BioSig Technologies, Inc. (NASDAQ:BSGM) CEO Kenneth Londoner said the company has made great strides on multiple fronts as it accelerates commercial momentum for developing a national installed base of its PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP systems. In a letter to shareholders, the company reported recent highlights including that the PURE EP system has now completed over 2,200 patient cases with 75 physicians at 17 hospitals across the United States, the strengthening of its management team, and the launch of its NOVA-5 software which offers greater customization and smarter workflows with the aim of further driving clinical adoption.
GlobeNewsWire
BioSig to Present at Heart Rhythm 2022
Tuesday Apr 19 2022 at 09:10
Company’s conference program to include physician presentations and technology demonstrations, including features of its newly released PURE EP(TM) Nova-5 Software Company’s conference program to include physician presentations and technology demonstrations, including features of its newly released PURE EP(TM) Nova-5 Software
GlobeNewsWire
BioSig to Present at NobleCon18 Capital Markets Conference
Thursday Apr 07 2022 at 08:30
Westport, CT, April 07, 2022 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, will be presenting at NobleCon18 – Noble Capital Markets’ Eighteenth Annual Investor Conference at the Hard Rock Hotel & Casino, Hollywood, Florida on Wednesday, April 20, 2022 at 9:30 AM ET. Conference attendees will also have the opportuntity to meet BioSig management during breakout sessions scheduled for 1:00 PM ET on Wednesday April 20, 2022.
Proactive Investors
BioSig Technologies completes its previously announced underwritten public offering for proceeds of $3 million
Wednesday Mar 23 2022 at 09:26
BioSig Technologies Inc has announced the completion of its previously announced underwritten public offering of 2,611,739 shares of its common stock at a price to the public of $1.15 per share for proceeds of $3 million. The company also said it has issued a cash warrant at $1.40, which if fully exercised will see the company receive another $3 million of cash proceeds.
Proactive Investors
BioSig Technologies to raise $3M in equity financing with family investment office
Tuesday Mar 22 2022 at 09:32
BioSig Technologies Inc announced that it has agreed to sell $3 million of its common stock and warrants to a family office, which the company said has deep expertise in small-cap emerging growth investing. BioSig noted the net proceeds from the offering will be used to fund working capital and continue commercialization activities related to the PURE EP System.
Proactive Investors
BioSig Technologies appoints John Sieckhaus as chief operating officer
Wednesday Mar 16 2022 at 09:53
BioSig Technologies Inc. has announced that John Sieckhaus will be joining the company as chief operating officer.
Proactive Investors
BioSig Technologies receives boost for its PURE EP technology with award of patent claims
Wednesday Jan 26 2022 at 14:10
BioSig Technologies Inc, the medtech group, has announced another boost for its heart monitoring technology, revealing that the US Patent Office had awarded patent claims for its PURE EP noise-filtering technology. The patent application was filed on November 6 last year and describes and claims computer-implemented methods for filtering noise from an input signal.
GlobeNewsWire
BioSig to Present at the 27th Annual International AF Symposium
Friday Jan 07 2022 at 10:20
PURE EP (TM) System to be highlighted in a Spotlight Session by DJ Lakkireddy, M.D., Kansas City Heart Rhythm Institute at HCA Midwest Health PURE EP (TM) System to be highlighted in a Spotlight Session by DJ Lakkireddy, M.D., Kansas City Heart Rhythm Institute at HCA Midwest Health
GlobeNewsWire
BioSig to Present at the 24th Annual Virtual Needham Growth Conference
Thursday Jan 06 2022 at 08:30
BioSig exits 2021 having completed more than 1800 patient cases with the PURE EP™ System. BioSig exits 2021 having completed more than 1800 patient cases with the PURE EP™ System.
Proactive Investors
BioSig Technologies looking to unlock the future of bioelectronic medicine
Tuesday Dec 21 2021 at 10:56
Using targeted electrical signals to harness the body’s natural mechanisms to diagnose and treat a range of diseases Has commercialized its first product, a biomedical signal processing platform called PURE EP To date more than 680 patient cases have been conducted with the PURE EP System across eight clinical sites. What BioSig Technologies does: BioSig Technologies Inc (NASDAQ:BSGM) is working to develop and deliver advanced signal processing solutions that will unlock the future of bioelectronic medicine.
Proactive Investors
BioSig Technologies selects Access Strategy Partners to accelerate commercial sales
Tuesday Dec 21 2021 at 10:54
BioSig Technologies Inc has announced the appointment of Access Strategy Partners, Inc (ASPI) to advise the company on the next phase of its commercial roll-out. BioSig said the healthcare management firm is expected to enhance the company’s market access strategy as BioSig expands the installation base of its signal processing technology for arrhythmia care.
Proactive Investors
BioSig Technologies expands its clinical footprint in Florida, installs PURE EP System in HCA Healthcare-operated hospital
Thursday Dec 16 2021 at 10:29
BioSig Technologies Inc said that it is installing a PURE EP System for an evaluation at the Hospital Corporation of America (HCA) Healthcare-operated Westside Regional Medical Center in Plantation, Florida. Westside Regional Medical Center is an award-winning, 250-bed hospital recognized for providing a wide array of services to the residents of Broward County, South Florida, and visitors from around the world.
GlobeNewsWire
BioSig to Host Conference Call on December 21, 2021
Monday Dec 13 2021 at 08:30
Westport, CT, Dec. 13, 2021 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it would host a conference call on Tuesday, December 21, 2021, at 2 PM ET.
Proactive Investors
BioSig Technologies appoints Gray Fleming as chief commercial officer
Wednesday Dec 01 2021 at 10:23
BioSig Technologies Inc has announced that Gray Fleming will be joining the company as its chief commercial officer. The Westport, Connecticut-based company said that Fleming will bring over 20 years of experience in the healthcare industry.
Proactive Investors
BioSig Technologies initiates Artificial Intelligence Development Program with Israel-based Technion
Tuesday Nov 16 2021 at 11:14
BioSig Technologies Inc said it has entered into a feasibility study with Haifa, Israel-based Technion Research & Development Foundation Ltd. The Westport, Connecticut-based company said that the feasibility program will be led by Joachim Behar, Head of the Artificial Intelligence in Medicine Laboratory (AIMLab) at Technion.
Proactive Investors
BioSig Technologies adds to its growing clinical footprint in Texas
Wednesday Nov 10 2021 at 10:19
BioSig Technologies Inc announced that it is installing the company’s seventeenth PURE EP system — a computerized system measuring and calculating electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures — for an evaluation at the HCA Healthcare-operated Medical City Heart Hospital in Dallas, Texas. Opened in 2019, Medical City Heart Hospital — a cardiovascular department of Medical City Dallas Hospital — provides the most comprehensive heart and vascular treatment in the Southwest.
BioSig Technologies Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
BioSig Technologies’s Altman Z-score is -100.64 which is in the distress zone. This indicates a higher risk of financial distress and potential bankruptcy for the company. It can serve as a warning sign of significant financial challenges, requiring careful consideration by potential investors.
Derived from SEC.GOV filing dataopen_in_new
BioSig Technologies Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, 1 insider has bought $45.25K of common stock in BioSig Technologies on the stock market with no insider selling.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
BioSig Technologies’s Income Quality of 0.62 is in line with its Industry Group of 0.68 (-8.8% lower)
BioSig Technologies’s Income Quality of 0.62 is lower than its Major Industry Group of 0.71 (-12.7% lower)
BioSig Technologies’s Income Quality of 0.62 is lower than its Sector of 0.75 (-17.3% lower)
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
BioSig Technologies’s Current Ratio of 0.6 is lower than its Industry Group of 3.36 (-82.1% lower)
BioSig Technologies’s Current Ratio of 0.6 is lower than its Major Industry Group of 3.13 (-80.8% lower)
BioSig Technologies’s Current Ratio of 0.6 is lower than its Sector of 2.6 (-76.9% lower)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (-1.25 & -1.02)
Cannot compare a negative PE Ratio (-1.25 & -0.58)
Cannot compare a negative PE Ratio (-1.25 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
BioSig Technologies’s PB Ratio of 91.34 is greater than its Industry Group of 1.9 (4707.4% greater)
BioSig Technologies’s PB Ratio of 91.34 is greater than its Major Industry Group of 1.93 (4632.6% greater)
BioSig Technologies’s PB Ratio of 91.34 is greater than its Sector of 1.62 (5538.3% greater)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
BioSig Technologies’s ROE of -72.94 is lower than its Industry Group of -0.26 (-27953.8% lower)
BioSig Technologies’s ROE of -72.94 is lower than its Major Industry Group of -0.09 (-80944.4% lower)
BioSig Technologies’s ROE of -72.94 is lower than its Sector of -0.03 (-243033.3% lower)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
BioSig Technologies’s ROCE of -44.26 is lower than its Industry Group of -0.27 (-16292.6% lower)
BioSig Technologies’s ROCE of -44.26 is lower than its Major Industry Group of -0.14 (-31514.3% lower)
BioSig Technologies’s ROCE of -44.26 is lower than its Sector of -0.04 (-110550.0% lower)
Derived from SEC.GOV filing dataopen_in_new